In mice, cyclophosphamide treatment was found to increase gut barrier permeability, facilitating the movement of bacteria like Enterococcus hirae and Lactobacillus johnsonii to tumor-draining lymph nodes, where they skewed CD4 + T cells in the TME toward a T helper 17 (TH17) phenotype, thereby improving tumor control (Viaud et al., 2013). Here, CD4 is linked to neoplasm.